Rethinking Early Access: Patient Safety First –
Early access to new drugs is often framed as compassionate and patient-centered, but it can backfire. Without solid evidence, patients may be exposed to unknown risks, driven by hype rather than data, and pushed into decisions that prioritize speed, profits, or novelty over real benefit. In some cases, early access doesn’t accelerate better care —…